Onco Cell Therapy Summit Europe 2022

OCTS EU 2022

Delivering safe and effective adoptive cell therapy products to clinical promise, commercial scale manufacturing and patients

Download Past Agenda
Amsterdam, The Netherlands
2-3 November, 2022

“The event was very interesting and well organised. I liked the mixture of scientific talks with updates on current developments alongside more practical 'logistical and regulatory' issues one encounters in the daily life of delivering these treatments to patients in clinical trials.”

Bilyana Popova, Senior Trial Co-ordinator, UCL

Why Attend

The Onco Cell Therapy Summit is returning face-to-face in Amsterdam as the hub of the European cell therapy industry.

Realise the full potential of your cell therapy biotechnology. Join talks exploring novel target discovery platforms, engineering cells to overcome the tumour microenvironment, automating manufacturing & analytics and next-generation pre-clinical models.

Europe is a powerhouse of research, but has been struggling to keep pace with development in the US. Get multiple perspectives in panels how to attract investment from C-suite executives and investors themselves, and explore European regulatory and reimbursement challenges for the cell therapy field.

Make the most of the end of restrictions, and catch up with peers and form new connections in our 5+ hours of networking time to share details and explore partnership opportunities, all made effortless through our networking app.

Mission Statement

With J&J’s landmark BCMA CAR-T approval marking the 6th approved CAR-T therapy, the cancer cell therapy field has definitively progressed beyond its nascent stage. Europe is a hub of research activity in the CGT space, and is home to industry-leading biotechs developing cell therapies that are more advanced, efficacious and accessible.

Despite this, Europe faces significant challenges with investment, regulation and staffing, alongside the wider R&D challenges in the field of developing more affordable therapies, treatments for solid tumors, and off-the-shelf allogeneic products.

The Onco Cell Therapy Summit Europe is the only event on mainland Europe bringing together industry experts in cancer cell therapy. The conference covers the full range of autologous and allogeneic modalities, and will explore in-depth the challenges across R&D, manufacturing, logistics, regulation and investment.

LEADING INDUSTRY MINDS FROM OUR PREVIOUS EVENT

 

Adrian Bot

VP Translational Medicine
Kite Pharma

Adrian Bot

VP Translational Medicine
Kite Pharma

Adrian Bot

VP Translational Medicine
Kite Pharma
 

Dr. Christina Coughlin

Chief Medical Officer & Executive Vice President
Tmunity

Dr. Christina Coughlin

Chief Medical Officer & Executive Vice President
Tmunity

Dr. Christina Coughlin

Chief Medical Officer & Executive Vice President
Tmunity
 

Michael Hudecek

Director CAR-T Program
Universitätsklinikum Würzburg, Germany

Michael Hudecek

Director CAR-T Program
Universitätsklinikum Würzburg, Germany

Michael Hudecek

Director CAR-T Program
Universitätsklinikum Würzburg, Germany
 

Jason Litten

CMO
Artiva

Jason Litten

CMO
Artiva

Jason Litten

CMO
Artiva
 

Dan Kaufman

Professor of Medicine – Division of Regenerative Medicine
UCSD

Dan Kaufman

Professor of Medicine – Division of Regenerative Medicine
UCSD

Dan Kaufman

Professor of Medicine – Division of Regenerative Medicine
UCSD
 

Alice Brown

VP Research
GammaDelta Therapeutics

Alice Brown

VP Research
GammaDelta Therapeutics

Alice Brown

VP Research
GammaDelta Therapeutics
 

John Rossi

Senior Director
Kite Pharma

John Rossi

Senior Director
Kite Pharma

John Rossi

Senior Director
Kite Pharma
 

Blake Aftab

VP Preclinical and Translational Sciences
Atara Biotherapeutics

Blake Aftab

VP Preclinical and Translational Sciences
Atara Biotherapeutics

Blake Aftab

VP Preclinical and Translational Sciences
Atara Biotherapeutics
 

Tony Ho

Executive Vice President – Head of Research and Development
CRISPR Therapeutics

Tony Ho

Executive Vice President – Head of Research and Development
CRISPR Therapeutics

Tony Ho

Executive Vice President – Head of Research and Development
CRISPR Therapeutics
 

Steven Kanner

CSO
Caribou Biosciences

Steven Kanner

CSO
Caribou Biosciences

Steven Kanner

CSO
Caribou Biosciences
 

Dr John Maher

Clinical Senior Lecturer/Honorary Consultant/CSO
King's College London/Leucid Bio

Dr John Maher

Clinical Senior Lecturer/Honorary Consultant/CSO
King's College London/Leucid Bio

Dr John Maher

Clinical Senior Lecturer/Honorary Consultant/CSO
King's College London/Leucid Bio
 

Professor Ann Ager

Personal Chair, School of Medicine
Cardiff University

Professor Ann Ager

Personal Chair, School of Medicine
Cardiff University

Professor Ann Ager

Personal Chair, School of Medicine
Cardiff University
 

Dr Detlev Parow

Head of Department of Medicines, Therapeutic Appliances and Remedies
DAK-Gesundheit

Dr Detlev Parow

Head of Department of Medicines, Therapeutic Appliances and Remedies
DAK-Gesundheit

Dr Detlev Parow

Head of Department of Medicines, Therapeutic Appliances and Remedies
DAK-Gesundheit
 

Evren Alici

CEO
Vycellix

Evren Alici

CEO
Vycellix

Evren Alici

CEO
Vycellix
 

Prof. Torsten Tonn

Group Leader
Univesitat Dresden

Prof. Torsten Tonn

Group Leader
Univesitat Dresden

Prof. Torsten Tonn

Group Leader
Univesitat Dresden
 

Deepak Raj

Centre for Tumour Biology
Bart's Cancer Institute

Deepak Raj

Centre for Tumour Biology
Bart's Cancer Institute

Deepak Raj

Centre for Tumour Biology
Bart's Cancer Institute
 

Nick Huntington

Co-Founder and CSO
oNKo Innate

Nick Huntington

Co-Founder and CSO
oNKo Innate

Nick Huntington

Co-Founder and CSO
oNKo Innate
 

James Patterson

Founder
Auxolytic

James Patterson

Founder
Auxolytic

James Patterson

Founder
Auxolytic
 

Frank Thielmann

Director of Operational Excellence
Takeda

Frank Thielmann

Director of Operational Excellence
Takeda

Frank Thielmann

Director of Operational Excellence
Takeda
 

Eytan Breman

R&D Manager
Celyad Oncology

Eytan Breman

R&D Manager
Celyad Oncology

Eytan Breman

R&D Manager
Celyad Oncology
 

Hanspeter Gerber

CSO
3T Biosciences

Hanspeter Gerber

CSO
3T Biosciences

Hanspeter Gerber

CSO
3T Biosciences
 

Volker Huppert

COO
Glycostem

Volker Huppert

COO
Glycostem

Volker Huppert

COO
Glycostem
 

Robert Kochl

Group Leader
Kings College London

Robert Kochl

Group Leader
Kings College London

Robert Kochl

Group Leader
Kings College London
 

Darrell Irvine

Professor of Materials Science
MIT

Darrell Irvine

Professor of Materials Science
MIT

Darrell Irvine

Professor of Materials Science
MIT
 

Professor Graham Pockley

Director
John van Geest Research Centre, Nottingham Trent University

Professor Graham Pockley

Director
John van Geest Research Centre, Nottingham Trent University

Professor Graham Pockley

Director
John van Geest Research Centre, Nottingham Trent University
 

Stephen Feldman

Director of Manufacturing and Process Development
Stanford Center for Cancer Cell Therapy

Stephen Feldman

Director of Manufacturing and Process Development
Stanford Center for Cancer Cell Therapy

Stephen Feldman

Director of Manufacturing and Process Development
Stanford Center for Cancer Cell Therapy
 

Reagan Jarvis

CEO & Co-Founder
Anocca AB

Reagan Jarvis

CEO & Co-Founder
Anocca AB

Reagan Jarvis

CEO & Co-Founder
Anocca AB
 

Paul Rennert

President and CSO
Aleta Biotherapeutics

Paul Rennert

President and CSO
Aleta Biotherapeutics

Paul Rennert

President and CSO
Aleta Biotherapeutics
 

Dan Shelly

VP of Development
Prescient Therapeutics

Dan Shelly

VP of Development
Prescient Therapeutics

Dan Shelly

VP of Development
Prescient Therapeutics
 

Kenneth Warrington

Sr. Director, Business Development,
GenScript ProBio

Ken Warrington, PhD joined GenScript Probio in 2020 as Head of Strategy & Innovation and a Sr. Director of Business Development supporting their Gene & Cell Therapy CMC services.  Dr.

Kenneth Warrington

Sr. Director, Business Development,
GenScript ProBio

Kenneth Warrington

Sr. Director, Business Development,
GenScript ProBio

Ken Warrington, PhD joined GenScript Probio in 2020 as Head of Strategy & Innovation and a Sr. Director of Business Development supporting their Gene & Cell Therapy CMC services.  Dr. Warrington served on the faculty at the University of Florida focused on AAV vector development and transitioned into industry where he has served lead technical operation and business development roles for global contract testing and manufacturing organizations.  He is a co-founder and director of Lacerta Therapeutics and Chair of the Scientific Advisory Board at Biostem Life Sciences.  He has broad expertise across the viral vector product development continuum from discovery through GMP-compliant manufacturing to support IND-enabling preclinical and early stage clinical programs.

 

Dr. Avery Posey

Department of Pathology and Laboratory Medicine
University of Pennsyvania

Dr. Avery Posey

Department of Pathology and Laboratory Medicine
University of Pennsyvania

Dr. Avery Posey

Department of Pathology and Laboratory Medicine
University of Pennsyvania
 

Marie Berger

PharmD
Myriade

Marie Berger

PharmD
Myriade

Marie Berger

PharmD
Myriade

WHO WILL BE THERE

45%
Biotech & Pharmaceutical Companies
15%
Cell Therapy Academics and Clinicians
20%
Biotechology Companies (Equipment, Materials & Logistics)
20%
Service Providers & Consultants

Biotech & Pharmaceutical Companies

Cell Therapy Academics and Clinicians

Biotechology Companies (Equipment, Materials & Logistics)

Service Providers & Consultants

PAST ATTENDEES

2022 Agenda

The Onco Cell Therapy Summit Europe 2022 Agenda is launching this summer!

In the meantime, take a look at some of our industry-leading speakers from our past Summits...

Past Speakers of OCTS Summits


Browse Top Industry Speakers

POSTER SUBMISSION

Are you looking to showcase your recent work to the Onco Cell Therapy Summit community?

Our dedicated poster session is the perfect way to get your research noticed. To present a poster, you need to register as a delegate. Please note that there is limited space available, and poster space is assigned on a first-come, first-served basis (subject to checks and successful registration). At the event, your presentation will be displayed in a dedicated poster area. The poster presentation session time of taking place is to be confirmed.

The poster abstract submission deadline is on 3rd June.

Abstracts received after this time may not be accepted, so please submit your abstract as soon as possible! Academics that submit a poster abstract before 3rd June get a 40% discount!

Posters should be sized A0 (841mm x 1189mm) in portrait orientation.

If you have any questions, please contact [email protected]

Click HERE to make a submission.

TESTIMONIALS

Resources

Download Resource

2021 Expertise Partners

2021 Tech Showcase Partner

2021 Event Partners

2021 Media Partners

Become a Partner

Kisaco Research provides the platform where industry executives can network, learn and meet potential industry partners.

Far from the typical ‘meet-and-greet’ experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand.

Your partnership with Kisaco Research will offer you a strategic approach that is an extension and enhancement of your own marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets.

Find out more by calling us at +44 (0)20 3696 2920 or email [email protected]

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us